276 related articles for article (PubMed ID: 15674912)
1. Rofecoxib for rheumatoid arthritis.
Garner SE; Fidan DD; Frankish RR; Judd MG; Towheed TE; Wells G; Tugwell P
Cochrane Database Syst Rev; 2005 Jan; 2005(1):CD003685. PubMed ID: 15674912
[TBL] [Abstract][Full Text] [Related]
2. Rofecoxib for the treatment of rheumatoid arthritis.
Garner S; Fidan D; Frankish R; Judd M; Towheed T; Wells G; Tugwell P
Cochrane Database Syst Rev; 2002; (3):CD003685. PubMed ID: 12137705
[TBL] [Abstract][Full Text] [Related]
3. Rofecoxib for the treatment of rheumatoid arthritis.
Garner S; Fidan D; Frankish R; Judd M; Towheed T; Wells G; Tugwell P
Cochrane Database Syst Rev; 2002; (2):CD003685. PubMed ID: 12076502
[TBL] [Abstract][Full Text] [Related]
4. Rofecoxib for osteoarthritis.
Garner SE; Fidan DD; Frankish R; Maxwell L
Cochrane Database Syst Rev; 2005 Jan; 2005(1):CD005115. PubMed ID: 15654705
[TBL] [Abstract][Full Text] [Related]
5. Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents.
Eccleston C; Cooper TE; Fisher E; Anderson B; Wilkinson NM
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD012537. PubMed ID: 28770976
[TBL] [Abstract][Full Text] [Related]
6. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis.
Jüni P; Nartey L; Reichenbach S; Sterchi R; Dieppe PA; Egger M
Lancet; 2004 Dec 4-10; 364(9450):2021-9. PubMed ID: 15582059
[TBL] [Abstract][Full Text] [Related]
7. Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia.
Jordan F; Quinn TJ; McGuinness B; Passmore P; Kelly JP; Tudur Smith C; Murphy K; Devane D
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD011459. PubMed ID: 32352165
[TBL] [Abstract][Full Text] [Related]
8. WITHDRAWN: Celecoxib for rheumatoid arthritis.
Garner SE; Fidan D; Frankish RR; Judd M; Shea B; Towheed T; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD003831. PubMed ID: 28598564
[TBL] [Abstract][Full Text] [Related]
9. Single dose oral rofecoxib for postoperative pain.
Barden J; Edwards J; Moore RA; McQuay HJ
Cochrane Database Syst Rev; 2005 Jan; (1):CD004604. PubMed ID: 15674955
[TBL] [Abstract][Full Text] [Related]
10. The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis.
Watson DJ; Yu Q; Bolognese JA; Reicin AS; Simon TJ
Curr Med Res Opin; 2004 Oct; 20(10):1539-48. PubMed ID: 15462687
[TBL] [Abstract][Full Text] [Related]
11. Celecoxib for rheumatoid arthritis.
Garner S; Fidan D; Frankish R; Judd M; Shea B; Towheed T; Wells G; Tugwell P
Cochrane Database Syst Rev; 2002; (4):CD003831. PubMed ID: 12519610
[TBL] [Abstract][Full Text] [Related]
12. Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study.
Hawkey CJ; Laine L; Simon T; Quan H; Shingo S; Evans J;
Gut; 2003 Jun; 52(6):820-6. PubMed ID: 12740337
[TBL] [Abstract][Full Text] [Related]
13. Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.
Miao XP; Li JS; Ouyang Q; Hu RW; Zhang Y; Li HY
Cochrane Database Syst Rev; 2014 Oct; (10):CD007744. PubMed ID: 25340915
[TBL] [Abstract][Full Text] [Related]
14. Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial.
Lisse JR; Perlman M; Johansson G; Shoemaker JR; Schechtman J; Skalky CS; Dixon ME; Polis AB; Mollen AJ; Geba GP;
Ann Intern Med; 2003 Oct; 139(7):539-46. PubMed ID: 14530224
[TBL] [Abstract][Full Text] [Related]
15. Single dose oral rofecoxib for acute postoperative pain in adults.
Bulley S; Derry S; Moore RA; McQuay HJ
Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD004604. PubMed ID: 19821329
[TBL] [Abstract][Full Text] [Related]
16. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS
Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470
[TBL] [Abstract][Full Text] [Related]
17. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
Bombardier C; Laine L; Reicin A; Shapiro D; Burgos-Vargas R; Davis B; Day R; Ferraz MB; Hawkey CJ; Hochberg MC; Kvien TK; Schnitzer TJ;
N Engl J Med; 2000 Nov; 343(21):1520-8, 2 p following 1528. PubMed ID: 11087881
[TBL] [Abstract][Full Text] [Related]
18. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
Hochberg MC
Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
[TBL] [Abstract][Full Text] [Related]
19. Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis.
Matheson AJ; Figgitt DP
Drugs; 2001; 61(6):833-65. PubMed ID: 11398914
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the comparative efficacy and tolerability of rofecoxib and naproxen in children and adolescents with juvenile rheumatoid arthritis: a 12-week randomized controlled clinical trial with a 52-week open-label extension.
Reiff A; Lovell DJ; Adelsberg JV; Kiss MH; Goodman S; Zavaler MF; Chen PY; Bolognese JA; Cavanaugh P; Reicin AS; Giannini EH
J Rheumatol; 2006 May; 33(5):985-95. PubMed ID: 16583464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
